Source comparison
Melanotan-1 vs Melanotan-2 — Mechanism & Safety Differences
The difference between Melanotan-1 and Melanotan-2 runs far deeper than tanning speed or dosing convenience. One is an FDA-approved medication with an established safety profile for rare photodermatoses. The other is a grey-market peptide with documented cardi
This comparison does not assign a generated winner or score.
- The difference between Melanotan-1 and Melanotan-2 runs far deeper than tanning speed or dosing convenience. One is an FDA-approved medication with an established safety profile for rare photodermatoses. The other is a grey-market peptide with documented cardiovascular and sexual side effects that most users don't anticipate. Both are alpha-melanocyte-stimulating hormone (α-MSH) analogs that bind melanocortin receptors, but Melanotan-2's non-selective binding across MC3R, MC4R, and MC5R receptors produces systemic effects that extend well beyond skin pigmentation.
- Our team has reviewed this across hundreds of research inquiries in this space. The pattern is consistent every time: researchers assume structural similarity means functional equivalence, which is incorrect.
- What is the difference between Melanotan-1 and Melanotan-2?
- Melanotan-1 (afamelanotide) is a linear 13-amino-acid peptide with high MC1R receptor selectivity, FDA-approved under the brand name Scenesse for erythropoietic protoporphyria and vitiligo. Melanotan-2 is a cyclic 7-amino-acid peptide with broader melanocortin receptor affinity, producing faster tanning but also erectile effects, nausea, and cardiovascular changes. The primary difference lies in receptor specificity. Melanotan-1 acts almost exclusively on MC1R in melanocytes, while Melanotan-2 activates MC1R, MC3R, MC4R, and MC5R across multiple tissue types.
- The two peptides share the same ancestral molecule. Α-MSH. But diverge sharply in clinical application and regulatory standing. Melanotan-1 underwent Phase III clinical trials, received European Medicines Agency approval in 2014, and FDA orphan drug designation in 2019. Melanotan-2 has never cleared Phase III trials for any indication and remains unregulated in research and cosmetic contexts. This regulatory gap matters: Melanotan-2's side-effect profile includes dose-dependent hypertension, spontaneous erections, and flushing that limits practical dosing ranges for many users. This piece covers receptor binding differences, clinical trial data for both peptides, side-effect mechanisms, and what those differences mean for research applications or therapeutic use.